TON - June 2022 Vol 15, No 3

The Abramson Cancer Center at Penn Medicine Chester County Hospital, based in West Chester, PA, is a Commission on Cancer–accredited oncology program dedicated to providing patients with accessible state-of-the-art care in a community hospital setting. Read More ›

Patients with cancer and immunoglobulin deficiency have compromised immune systems–based response to COVID-19 vaccines. A team of researchers in Germany has developed a multipeptide COVID-19 vaccine that boosts immunity in immunocompromised patients, according to results of a phase 1/2 trial reported at the 2022 American Association for Cancer Research annual meeting. Read More ›

On the second day of the 2022 Cholangiocarcinoma Foundation annual meeting, Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Harvard Medical School, and Lead, Liver Cancer Research Program, Massachusetts General Hospital Cancer Center, Boston, presented a clinical update on emerging systemic therapies in cholangiocarcinoma (CCA). Read More ›

Telehealth is playing a larger role in the delivery of cancer care, but there is more work that needs to be done to permanently increase access, according to a panel of experts during a plenary session at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference. Read More ›

In this issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles designed to inform and empower nurses, navigators, and advanced practice providers who work to improve the clinical outcomes and quality of life of patients in all stages of the cancer care journey. Read More ›

The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline. Read More ›

Updates to the screening guidelines for colorectal cancer (CRC) from the National Comprehensive Cancer Network (NCCN) include lowering the initial screening age for average-risk individuals and second- and third-degree family members with CRC, as well as an extension in the interval for surveillance colonoscopy for low-risk individuals. Read More ›

Treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the neoadjuvant setting plus adjuvant nivolumab resulted in a high rate of pathologic complete response (pCR) in patients with resectable microsatellite instable (MSI)/mismatch repair deficient (dMMR) oeso-gastric junction (OGJ) adenocarcinoma, according to findings from the GERCOR NEONIPIGA clinical trial, which were presented by Thierry André, MD, Professor, Medical Oncology, Sorbonne Université, Hôpital Saint Antoine, Paris, France, at the 2022 ASCO Gastrointestinal Cancers Symposium. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between April 1, 2022, and May 25, 2022. Read More ›

The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial, which were presented at the 2022 ASCO Genitourinary Cancers Symposium by Petros Grivas, MD, PhD, Clinical Director, Genitourinary Cancers Program, University of Washington School of Medicine, Seattle, and Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle. Read More ›

Page 1 of 2


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: